Plain English Summary
Background and study aims
Transitions of care from hospital to home can be risky, especially for older people with multiple health conditions. Previous research has suggested that the post-discharge period may be improved by better involving patients and families in their care. This study forms part of a programme of research which aims to develop an intervention to improve the safety and experience of transitions from hospital to home for people aged 75 years and over.
Who can participate?
Patients aged 75 and over who are community-dwelling at the time of admission and anticipated to be discharged to their own home or that of a relative.
What does the study involve?
A minimum of 200 patients will provide informed consent to complete a questionnaire at three-time points postdischarge and for routine data about their care to be collected from medical records. On intervention wards, a subset of 20-24 of these patients will also consent to a qualitative evaluation of the intervention (interviews and observation). Up to 28 staff will be interviewed to gain their views on the intervention.
What are the possible benefits and risks of participating?
There are no direct benefits to taking part in the study. However, it may help improve future services to support older people as they transition from hospital to home. As a small token of our appreciation for their support, participants will receive a £5 gift voucher with each questionnaire. We do not think that there are any disadvantages or risks to participating in the study.
Where is the study run from?
1. Mid Yorkshire Hospitals NHS Trust
2. Airedale NHS Foundation Trust
3. Leeds Teaching Hospitals NHS Trust
When is the study starting and how long is it expected to run for?
September 2019 to July 2020 (updated 10/01/2020, previously: April 2020)
Who is funding the study?
National Institute for Health Research (NIHR), UK
Who is the main contact?
1. Dr Ruth Baxter
ruth.baxter@bthft.nhs.uk
2. Dr Jenni Murray
Jenni.Murray@bthft.nhs.uk
Trial website
https://yqsr.org/our-research-programmes/partners-at-care-transitions-pact/
Contact information
Type
Scientific
Primary contact
Dr Ruth Baxter
ORCID ID
http://orcid.org/0000-0002-7631-2786
Contact details
Yorkshire Quality and Safety Research Group
Bradford Institute for Health Research
Bradford Teaching Hospitals NHS Foundation Trust
Duckworth Lane
Bradford
BD9
United Kingdom
01274 38 3421
ruth.baxter@bthft.nhs.uk
Type
Scientific
Additional contact
Dr Jenni Murray
ORCID ID
Contact details
Yorkshire Quality and Safety Research Group
Bradford Institute for Health Research
Bradford Teaching Hospitals NHS Foundation Trust
Duckworth Lane
Bradford
BD9
United Kingdom
01274 383667
Jenni.Murray@bthft.nhs.uk
Additional identifiers
EudraCT number
Nil known
ClinicalTrials.gov number
Nil known
Protocol/serial number
42191
Study information
Scientific title
Partners at Care Transitions (PACT): Improving patient experience and safety at transitions of care - Assessing the feasibility of using the PACT intervention to improve safety and experience of the transition process in a randomised controlled trial setting.
Acronym
PACT
Study hypothesis
This study explores the feasibility of the PACT intervention and trial methodology to refine the intervention and inform the decision whether or not to proceed to a full cluster randomised controlled trial. The following objectives will be addressed:
1. Explore the acceptability, usefulness and feasibility of intervention components to patients and carers
2. Explore the acceptability, usefulness and feasibility of intervention and implementation components to ward staff
3. Assess the feasibility of methods to identify, recruit and retain patients in the trial and determine the best way to follow-up patients in this population
4. To identify the required approach for obtaining hospital emergency readmission data:
a. To explore the most accurate and feasible way of obtaining these data for consented participants
b. To explore the most accurate and feasible way of obtaining non-identifiable readmission data for non-consented participants
c. To identify the optimal time period over which baseline readmission data should be collected
5. To identify the required approach for obtaining health economic data
6. To optimise the intervention and implementation & training package
7. To explore how we might measure fidelity of the intervention
8. To inform the development of a definitive protocol for the cRCT
Ethics approval
Approved 27/06/2019, NHS HRA Wales REC 7 (ADDRESS; 01874 615949; Wales.REC7@wales.nhs.uk), ref: 19/WA/0162
Study design
Feasibility cluster randomised controlled trial
Primary study design
Interventional
Secondary study design
Cluster randomised trial
Trial setting
Hospitals
Trial type
Other
Patient information sheet
Not available in web format, please use contact details to request a participant information sheet
Condition
No specific condition. Patients will have been admitted to hospital for care for conditions such as stroke, COPD, infection, or with injuries from falls. It is not possible to know in advance what conditions the patients will have because we are recruiting from a range of hospital specialties which are likely to include stroke, respiratory, cardiology, and elderly medical wards. Patients may have dementia and/or acute delirium alongside their presenting complaint.
Intervention
A feasibility cluster randomised controlled trial will be conducted across 10 wards clustered within three acute NHS trusts. Wards will be randomised in an unequal allocation ratio (3:2) with six randomised to the intervention and four to usual care. Blinding will not used due to this unequal allocation. Recruitment and follow up of patients within each ward will take place over a 7 month period.
Randomisation will be done using naïve minimisation with a base probability 1.0 (i.e. deterministic minimisation) will be conducted using the following key wards characteristics: ward type (speciality), the percentage of patients over 75 years, and NHS Trust.
Intervention wards will deliver the Partners At Care Transitions (PACT) intervention - a patient-facing intervention which seeks to improve the safety and experience of older people as they transition from hospital to home. Control wards will deliver usual care to their patients.
A minimum of 200 patients (approximately 20 patients per ward) will be recruited to participate in the trial. Participants will provide informed consent to: baseline data collection at the point of recruitment; follow-up questionnaires to assess patient reported outcomes at three points post discharge (up to 21 days post discharge, 30 days and 90 days post-discharge); and access to their medical records to gather routinely collected data (e.g. readmissions post discharge, and information about co-morbidities). Depending on their preferences, patients may be followed-up by post, telephone or email. At the 30 day follow-up, if patients received a copy of the PACT intervention while they were in hospital, patients will be asked to return it to the research team.
Within the sample of 200 patients, a nested sub-sample of between 20-24 patients will be recruited to participate in a qualitative assessment of feasibility. If relevant, the informal carers of these patients will also be recruited. In addition to completing the trial procedures outlined above, these participants will consent to the observation of their care while they are in hospital, and up to two interviews (post-discharge and 30 days post-discharge). Field notes will be taken during observations, and interviews lasting between 30 and 60 minutes and will be audio-recorded and transcribed. In addition, up to 28 staff members (24 from intervention wards and 4 from control wards) will be invited to participate in an interview lasting between 15 and 30 minutes. Ward level observations and informal conversations will also be conducted on participating wards.
In addition, this study seeks to identify an efficient and accurate way of accessing readmission data for patients who are discharged to their own homes rather than other usual places of residence (e.g. nursing homes). Confidentiality Advisory Group advice will be gained to access the medical records of 100 patients without their consent to assess their actual discharge destinations (own home vs nursing/care home or other).
The findings from this study will be used to optimise the intervention, implementation package, and the trial methodology, and ultimately inform the decision about whether to proceed to a full trial.
Intervention type
Behavioural
Phase
Drug names
Primary outcome measure
30-day emergency hospital readmission measured using patient records
Secondary outcome measures
1. Safety and experience of older people during transitions from hospital to home measured using the Patient At Care Transitions Measure (PACT – M); Timepoint(s): up to 21, 30 and 90 days post-discharge
2. Patient-centred quality of care transitions measured using the Care Transitions Measure 3 items (CTM-3); Timepoint(s): up to 21, 30 and 90 days post-discharge
3. Quality of life measured using the EuroQol 5-Dimension Health Questionnaire (5 levels) (EQ5D-5L) and Proxy EQ5D-5L; Timepoint(s): up to 21, 30 and 90 days post-discharge
4. Healthcare resource use measured using an adapted version of Client Service Receipt Inventory (CSRI); Timepoint(s): up to 21, 30 and 90 days post-discharge
5. Utility of the intervention measured using...
Overall trial start date
19/11/2018
Overall trial end date
31/07/2020
Reason abandoned (if study stopped)
Eligibility
Participant inclusion criteria
1. Aged 75 and over
2. Community-dwelling at the time of admission and anticipated to be discharged to their own home or that of a relative (this can include a period of rehabilitation after hospital discharge)
3. Staying for at least one night on a participating ward
4. Ability to read and understand English
5. Willing and able to give informed consent (or personal consultee if lacking in mental capacity)
For patients who lack capacity, eligible consultee/proxys (e.g. carers) will fulfil the following criteria:
1. A primary carer for the patient
2. Provides informal care to the patient (i.e. not paid / professional)
3. Willing to act as a consultee for the patient and/or willing and able to give informed consent to act as the patient’s proxy throughout the study.
4. Ability to read and understand English
Participant type
Patient
Age group
Senior
Gender
Both
Target number of participants
Planned Sample Size: 228; UK Sample Size: 228
Participant exclusion criteria
1. Out of area patients and/or patients who are to be transferred to another hospital
2. Admitted for psychiatric reasons (other than dementia/delirium)
3. Nursing/residential home resident or planning to be discharged to a nursing / residential home on a permanent basis
4. Less than one overnight stay (on the participating ward) at time of recruitment
5. Identified as being at the end of their life/subject to fast-track discharge to palliative care
6. Unable to read and understand English
7. Unable to give informed consent and where a suitable personal consultee cannot be identified, or if no one is prepared to act as a consultee for the patient
Recruitment start date
02/09/2019
Recruitment end date
31/03/2020
Locations
Countries of recruitment
United Kingdom
Trial participating centre
Mid Yorkshire Hospitals NHS Trust
Rowan House
Aberford Road
Wakefield
WF1 4EE
United Kingdom
Trial participating centre
Airedale NHS Foundation Trust
Airedale General Hospital
Skipton Road
Steeton
Keighley
BD20 6TD
United Kingdom
Trial participating centre
Leeds Teaching Hospitals NHS Trust
St. James's University Hospital
Beckett Street
Leeds
LS9 7TF
United Kingdom
Sponsor information
Organisation
Bradford Teaching Hospitals NHS Foundation Trust
Sponsor details
Bradford Institute for Health Research
Bradford Royal Infirmary
Duckworth Lane
Bradford
BD9 6RJ
United Kingdom
01274 382575
Jane.Dennison@bthft.nhs.uk
Sponsor type
Hospital/treatment centre
Website
Funders
Funder type
Government
Funder name
NIHR Central Commissioning Facility (CCF); Grant Codes: RP-PG-1214-20017
Alternative name(s)
Funding Body Type
Funding Body Subtype
Location
Results and Publications
Publication and dissemination plan
The research team is committed to utilising a diverse range of dissemination methods to ensure that the research findings are widely shared with audiences including the research community, patients & the public, practitioners and policy makers. We intend to publish the feasibility trial protocol and full results in scientific peer reviewed journals, and will disseminate our findings via academic conferences, healthcare improvement events, and within our local community. The NIHR will be notified of all outputs.
IPD sharing statement:
The current data sharing plans for this study are unknown and will be available at a later date
Intention to publish date
31/12/2021
Participant level data
To be made available at a later date
Basic results (scientific)
Publication list
2020 protocol in https://pubmed.ncbi.nlm.nih.gov/32905158/ (added 11/09/2020)